Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Jan 21;7(1):e18396.
doi: 10.2196/18396.

Cardiovascular Assessment Tool for Breast Cancer Survivors and Oncology Providers: Usability Study

Affiliations

Cardiovascular Assessment Tool for Breast Cancer Survivors and Oncology Providers: Usability Study

Kathryn E Weaver et al. JMIR Cancer. .

Abstract

Background: Cardiovascular health is of increasing concern to breast cancer survivors and their health care providers, as many survivors are more likely to die from cardiovascular disease than cancer. Implementing clinical decision support tools to address cardiovascular risk factor awareness in the oncology setting may enhance survivors' attainment or maintenance of cardiovascular health.

Objective: We sought to evaluate survivors' awareness of cardiovascular risk factors and examine the usability of a novel electronic health record enabled cardiovascular health tool from the perspective of both breast cancer survivors and oncology providers.

Methods: Breast cancer survivors (n=49) recruited from a survivorship clinic interacted with the cardiovascular health tool and completed pre and posttool assessments about cardiovascular health knowledge and perceptions of the tool. Oncologists, physician assistants, and nurse practitioners (n=20) who provide care to survivors also viewed the cardiovascular health tool and completed assessments of perceived usability and acceptability.

Results: Enrolled breast cancer survivors (84% White race, 4% Hispanic ethnicity) had been diagnosed 10.8 years ago (SD 6.0) with American Joint Committee on Cancer stage 0, I, or II (45/49, 92%). Prior to viewing the tool, 65% of survivors (32/49) reported not knowing their level for one or more cardiovascular health factors (range 0-4). On average, only 45% (range 0%-86%) of survivors' known cardiovascular health factors were at an ideal level. More than 50% of survivors had ideal smoking status (45/48, 94%) or blood glucose level (29/45, 64%); meanwhile, less than 50% had ideal blood pressure (12/49, 24%), body mass index (12/49, 24%), cholesterol level (17/35, 49%), diet (7/49, 14%), and physical activity (10/49. 20%). More than 90% of survivors thought the tool was easy to understand (46/47, 98%), improved their understanding (43/47, 91%), and was helpful (45/47, 96%); overall, 94% (44/47 survivors) liked the tool. A majority of survivors (44/47, 94%) thought oncologists should discuss cardiovascular health during survivorship care. Most (12/20, 60%) oncology providers (female: 12/20, 60%; physicians: 14/20, 70%) had been practicing for more than 5 years. Most providers agreed the tool provided useful information (18/20, 90%), would help their effectiveness (18/20, 90%), was easy to use (20/20, 100%), and presented information in a useful format (19/20, 95%); and 85% of providers (17/20) reported they would use the tool most or all of the time when providing survivorship care.

Conclusions: These usability data demonstrate acceptability of a cardiovascular health clinical decision support tool in oncology practices. Oncology providers and breast cancer survivors would likely value the integration of such apps in survivorship care. By increasing awareness and communication regarding cardiovascular health, electronic health record-enabled tools may improve survivorship care delivery for breast cancer and ultimately patient outcomes.

Keywords: breast cancer; cancer survivors; cardiovascular diseases; clinical decision support; electronic health records; usability testing.

PubMed Disclaimer

Conflict of interest statement

Conflicts of Interest: None declared.

Figures

Figure 1
Figure 1
Adapted AH-HA tool (top) and the Vigor-Us tool (bottom).
Figure 2
Figure 2
Proportion of breast cancer survivors (n=49) reporting poor (red), intermediate (yellow), ideal (green), and missing (gray) cardiovascular health factors. CVH: cardiovascular health.
Figure 3
Figure 3
Survivor characterization of cardiovascular health factors. CVH: cardiovascular health; EHR: electronic health record.
Figure 4
Figure 4
Usability ratings of the tools among breast cancer survivors and oncology providers. CVH: cardiovascular health.
Figure 5
Figure 5
Proportion of breast cancer survivors (n=47) whose cardiovascular health perceptions changed before and after viewing the assessment tool.

Similar articles

Cited by

References

    1. Shelburne N, Adhikari B, Brell J, Davis M, Desvigne-Nickens P, Freedman A, Minasian L, Force T, Remick SC. Cancer treatment-related cardiotoxicity: current state of knowledge and future research priorities. J Natl Cancer Inst. 2014 Sep;106(9) doi: 10.1093/jnci/dju232. http://www.iom.edu/~/media/Files/Report%20Files/2005/From-Cancer-Patient... - DOI - PMC - PubMed
    1. Mehta LS, Watson KE, Barac A, Beckie TM, Bittner V, Cruz-Flores S, Dent S, Kondapalli L, Ky B, Okwuosa T, Piña Ileana L, Volgman AS, American Heart Association Cardiovascular Disease in WomenSpecial Populations Committee of the Council on Clinical Cardiology; Council on CardiovascularStroke Nursing;Council on Quality of CareOutcomes Research Cardiovascular disease and breast cancer: where these entities intersect: a scientific statement from the American Heart Association. Circulation. 2018 Feb 20;137(8):e30–e66. doi: 10.1161/CIR.0000000000000556. http://europepmc.org/abstract/MED/29437116 - DOI - PMC - PubMed
    1. Hanrahan EO, Gonzalez-Angulo AM, Giordano SH, Rouzier R, Broglio KR, Hortobagyi GN, Valero V. Overall survival and cause-specific mortality of patients with stage T1a,bN0M0 breast carcinoma. JCO. 2007 Nov 01;25(31):4952–4960. doi: 10.1200/jco.2006.08.0499. - DOI - PubMed
    1. Chapman JW, Meng D, Shepherd L, Parulekar W, Ingle JN, Muss HB, Palmer M, Yu C, Goss PE. Competing causes of death from a randomized trial of extended adjuvant endocrine therapy for breast cancer. J Natl Cancer Inst. 2008 Feb 20;100(4):252–260. doi: 10.1093/jnci/djn014. http://europepmc.org/abstract/MED/18270335 - DOI - PMC - PubMed
    1. Bradshaw PT, Stevens J, Khankari N, Teitelbaum SL, Neugut AI, Gammon MD. Cardiovascular disease mortality among breast cancer survivors. Epidemiology. 2016 Jan;27(1):6–13. doi: 10.1097/EDE.0000000000000394. http://europepmc.org/abstract/MED/26414938 - DOI - PMC - PubMed

LinkOut - more resources